Literature DB >> 24013763

New-generation therapy for ANCA-associated vasculitis.

David Jayne1.   

Abstract

Newer therapies for systemic vasculitis are required to improve the efficacy and reduce the toxicity associated with current agents. Our understanding of its pathogenesis is increasing with the availability of targeted therapies. B-cell depletion with rituximab is now a licensed therapy for ANCA vasculitis. Targets for therapy currently in development in ANCA associated vasculitis include blockade of complement and pro-inflammatory cytokines, and inhibition of T cell co-stimulation.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24013763     DOI： 10.1007/s10157-013-0855-z

Source DB:  PubMed          Journal:  Clin Exp Nephrol        ISSN： 1342-1751            Impact factor:   2.801


  20 in total

1.  Measurement of damage in systemic vasculitis: a comparison of the Vasculitis Damage Index with the Combined Damage Assessment Index.

Authors:  Ravi Suppiah; Oliver Flossman; Chetan Mukhtyar; Federico Alberici; Bo Baslund; Denise Brown; Nadeem Hasan; Julia Holle; Zdenka Hruskova; David Jayne; Andrew Judge; Mark A Little; Peter A Merkel; Alessandra Palmisano; Philip Seo; Coen Stegeman; Vladimir Tesar; Augusto Vaglio; Kerstin Westman; Raashid Luqmani
Journal:  Ann Rheum Dis       Date:  2010-08-24       Impact factor: 19.103

2.  Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.

Authors:  Rachel B Jones; Jan Willem Cohen Tervaert; Thomas Hauser; Raashid Luqmani; Matthew D Morgan; Chen Au Peh; Caroline O Savage; Mårten Segelmark; Vladimir Tesar; Pieter van Paassen; Dorothy Walsh; Michael Walsh; Kerstin Westman; David R W Jayne
Journal:  N Engl J Med       Date:  2010-07-15       Impact factor: 91.245

3.  Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis.

Authors:  Rona M Smith; Rachel B Jones; Mary-Jane Guerry; Simona Laurino; Fausta Catapano; Afzal Chaudhry; Kenneth G C Smith; David R W Jayne
Journal:  Arthritis Rheum       Date:  2012-11

4.  Churg-Strauss syndrome with poor-prognosis factors: A prospective multicenter trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in forty-eight patients.

Authors:  Pascal Cohen; Christian Pagnoux; Alfred Mahr; Jean-Pierre Arène; Luc Mouthon; Véronique Le Guern; Marie-Hélène André; Martine Gayraud; David Jayne; Daniel Blöckmans; Jean-François Cordier; Loïc Guillevin
Journal:  Arthritis Rheum       Date:  2007-05-15

5.  A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis.

Authors:  Rachel B Jones; Alastair J Ferraro; Afzal N Chaudhry; Paul Brogan; Alan D Salama; Kenneth G C Smith; Caroline O S Savage; David R W Jayne
Journal:  Arthritis Rheum       Date:  2009-07

6.  A model to predict cardiovascular events in patients with newly diagnosed Wegener's granulomatosis and microscopic polyangiitis.

Authors:  Ravi Suppiah; Andrew Judge; Rajbir Batra; Oliver Flossmann; Lorraine Harper; Peter Höglund; M Kassim Javaid; David Jayne; Chetan Mukhtyar; Kerstin Westman; John C Davis; Gary S Hoffman; W Joseph McCune; Peter A Merkel; E William St Clair; Philip Seo; Robert Spiera; John H Stone; Raashid Luqmani
Journal:  Arthritis Care Res (Hoboken)       Date:  2011-04       Impact factor: 4.794

7.  Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome.

Authors:  Sophia Kim; Gautham Marigowda; Eyal Oren; Elliot Israel; Michael E Wechsler
Journal:  J Allergy Clin Immunol       Date:  2010-06       Impact factor: 10.793

8.  A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies.

Authors:  David Jayne; Niels Rasmussen; Konrad Andrassy; Paul Bacon; Jan Willem Cohen Tervaert; Jolanta Dadoniené; Agneta Ekstrand; Gill Gaskin; Gina Gregorini; Kirsten de Groot; Wolfgang Gross; E Christiaan Hagen; Eduardo Mirapeix; Erna Pettersson; Carl Siegert; Alberto Sinico; Vladimir Tesar; Kerstin Westman; Charles Pusey
Journal:  N Engl J Med       Date:  2003-07-03       Impact factor: 91.245

9.  Deoxyspergualin in relapsing and refractory Wegener's granulomatosis.

Authors:  O Flossmann; B Baslund; A Bruchfeld; J W Cohen Tervaert; C Hall; P Heinzel; B Hellmich; R A Luqmani; K Nemoto; V Tesar; D R W Jayne
Journal:  Ann Rheum Dis       Date:  2008-08-19       Impact factor: 19.103

10.  Spleen tyrosine kinase is important in the production of proinflammatory cytokines and cell proliferation in human mesangial cells following stimulation with IgA1 isolated from IgA nephropathy patients.

Authors:  Min Jeong Kim; John P McDaid; Stephen P McAdoo; Jonathan Barratt; Karen Molyneux; Esteban S Masuda; Charles D Pusey; Frederick W K Tam
Journal:  J Immunol       Date:  2012-09-05       Impact factor: 5.422
View more
  2 in total

Review 1.  Eosinophilic granulomatosis with polyangiitis: an overview.

Authors:  Andrea Gioffredi; Federica Maritati; Elena Oliva; Carlo Buzio
Journal:  Front Immunol       Date:  2014-11-03       Impact factor: 7.561

2.  Retrospective comparison of high-resolution computed tomography of eosinophilic granulomatosis with polyangiitis with severe asthma.

Authors:  Xiaofeng Lin; Yuejiao Lin; Zhengdao Lai; Shushan Wei; Minzhi Qiu; Jianyu Li; Qin Liu; Kian Fan Chung; Qingsi Zeng; Qingling Zhang
Journal:  Ann Transl Med       Date:  2021-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.